Home > Journals > Medicine > European Journal of Dermatology > Full text
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections
All journals
Medicine
European Journal of Dermatology
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Biology and research
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Texte intégral de l'article
 
  Printable version

Breaking the relentless course of Hallopeau’s acrodermatitis by dapsone


European Journal of Dermatology. Volume 9, Number 2, 126-8, March 1999, Cas clinique


Summary  

Author(s) : A.F. Nikkels, N. Nikkels-Tassoudji, G.E. Piérard, Department of Dermatopathology, University of Liège, B-4000 Liège, Belgium, and Section of Dermatology, St Josef Hospital, St Vith, Belgium..

Summary : We report the case of a 74-year-old man who suffered for four years from recurrent generalized pustular eruptions associated with acrodermatitis continua of Hallopeau (ACH). Initial therapy using topical corticosteroids, tars and PUVA failed to improve the acral lesions. The disease was also unresponsive to systemic therapy using corticosteroids, methotrexate, etretinate, acitretine and cyclosporin A. Serious side-effects were experienced with these drugs. A marked improvement of the generalized pustules was observed under treatment combining etretinate and methotrexate, without having any effect on the acropustulosis. During hospitalization, a topical tar therapy cleared the pustular rash. Again no effect was observed on the acral lesions. Disulone (DDS) therapy, initiated at a dose of 200 mg/day, completely cleared ACH after 4 weeks. The disease relapsed when the dose was reduced to 100 mg/day. Increasing the DDS to 150 mg/day was rapidly followed by a new clearance of the acral lesions. After a 3-month treatment, the patient has remained lesion free and no DDS-related side-effects have occurred. In conclusion, sulfones may be considered as an alternative therapeutic option in drug-resistant ACH.

Keywords : acrodermatitis continua Hallopeau, neutrophils, psoriasis, sulfone, therapy, pustules.

Pictures


   
   Figure 1. Acrodermatitis continua suppurativa Hallopeau with onychomadesis and skin atrophy.



   
  

Figure 2. Marked improvement of acrodermatitis continua suppurativa Hallopeau during sulfone therapy.








 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]